37 results about "Treatment resistance" patented technology

Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type p53. Breast, ovarian, lung cancer and leukemia cells lines were treated with combinations of Akt activation inhibitor Triciribine (TCN) or Triciribine phosphate (TCNP) and chemotherapeutic drugs to determine the efficiency of combination therapy. Additionally, cells were introduced into xenograft models to determine in vivo effects of combination treatment. Combining TCN or TCNP with other anticancer drugs overcame cytotoxic or treatment resistance. Thus, TCN and TCNP are shown to broaden the spectrum of human tumors that can be effectively treated.

The invention belongs to the field of nuclear medicine, and relates to a dual-enzyme system probe and its application. The probe has a structure shown in formula I, wherein QD is a fluorescent group or a drug group; L is a linker with a structure shown in formula II; T is a PSMA-specific targeting group; Z is H, a nuclide chelate chelating group, radionuclide or nuclide chelating group with radionuclide chelated. The present invention is based on the prostate-specific membrane antigen PSMA targeting and Caspase-3 recognition strategy to deliver the dual-enzyme system nuclear medicine probe of drug molecules, which can target prostate cancer for radiotherapy sensitization treatment, and help to solve castration-resistant prostate It is expected to realize intraoperative navigation of prostate cancer. It provides more efficient tools for the detection and treatment of tumor therapy, and has broad application prospects.

The invention provides the application of a soluble form of Tim3 in immune checkpoint blockade treatment resistance, and belongs to the technical fields of biomedicine and molecular biology. The present invention has found through research that the soluble form of Tim3 is not only significantly up-regulated in NSCLC that does not respond to PD-1 blockade therapy, but also shows a higher serum level in cholangiocarcinoma, which has been reported to be resistant to PD-1 Blocking therapy has strong resistance. Importantly, the present invention found that sTim-3 induced resistance to PD-1 antibody blockade therapy in a mouse model of ICC and promoted tumor progression by suppressing T cell function in a CEACAM1-dependent manner. Therefore, human sTim‑3 can be used as a candidate biomarker for tumor progression and resistance to PD‑1 blockade therapy, and a new mechanism for Tim‑3-mediated immunosuppression and resistance to PD‑1 blockade therapy in the tumor environment was proposed , has good practical application value.

The invention designs a resistance wire, which is characterized in that it consists of the following composition and weight percentage: Cr 20——26%, Al 3——6%, Ti 0.15——0.4%, C0.01——0.03%, Si 0.04—0.1%, S 0.002—0.004%, Y0.4—0.6%, Mo0.1—0.2%, Fe balance. A pre-oxidation treatment method for resistance wire, which is characterized in that it consists of the following steps: (1) 5% to 10% (mass fraction) of ammonium citrate for pickling, at a temperature of 60°C, after 40 minutes, wash with cold water, and then Put in alkaline permanganate bath for 10 minutes, then wash in cold water for 2 minutes, (2) passivation agent HNO3 20% ~ 50% + Na2Cr207H20 22% ~ 6% (mass fraction); temperature 49 ~ 54 ℃; time 15 ~ 30min; or Temperature 21~38℃; time 30~60min, (3) descaling pickling agent H2SO48%~11% (volume fraction); temperature 66~82℃; time 5~45min, (4) heating 120-2000C for drying (5) Put pure oxygen into the furnace at 9000C, heat it for 30 minutes and then quickly heat it to 12000C, (6) After holding it for 3 hours, cool it to room temperature with the furnace. The invention has the advantages that the furnace wire after pre-oxidation treatment has uniform and dense oxidation mold, strong anti-corrosion ability and super strong insulation performance. Put an end to the previous oxide film "wrinkle skin" phenomenon.

The present invention recognizes that current clinical laboratory testing methods for multiparametric single cell analysis are limited to analysis of intact live cells, and are insufficient for identification of signaling activation profile defining certain cell types, including but not limited to neoplastic and immunologically activated cell subsets. One aspect of the present invention generally relates to marker selection in panels to include proteins routinely assessed in standard FCM, while preferably also incorporating markers for surface receptor proteins within activated signaling cascades. A further aspect of the present invention generally relates to panel design for the following indications in neoplastic and non-neoplastic clinical applications as examples of the technology: (a) identification of CML progenitor cell subsets in the setting of disease recurrence after treatment discontinuation or relapse due to treatment resistance, and (b) characterization of activated basophils to predict the severity of an allergic response. Another aspect of the present invention generally relates to methods to measure levels of surface and IC biomarkers in separate or combined assays for robust characterization of each or select cell compartment, and data analysis based on results from each or all method(s) used for optimal detection of the markers. A further aspect of the present invention generally relates to the identification and profiling of cell subpopulations based on analysis of surface markers including those associated with lineage and maturation of cell types and receptor proteins, and the corresponding IC phosphoproteins including those in activated signaling cascades to predict certain disease states or response to treatment.